Repurposing quinacrine for treatment-refractory cancer.

Autor: Oien DB; Division of Experimental Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, United States., Pathoulas CL; Division of Experimental Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, United States., Ray U; Division of Experimental Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, United States., Thirusangu P; Division of Experimental Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, United States., Kalogera E; Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, United States., Shridhar V; Division of Experimental Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, United States. Electronic address: shridhar.vijayalakshmi@mayo.edu.
Jazyk: angličtina
Zdroj: Seminars in cancer biology [Semin Cancer Biol] 2021 Jan; Vol. 68, pp. 21-30. Date of Electronic Publication: 2019 Sep 25.
DOI: 10.1016/j.semcancer.2019.09.021
Abstrakt: Quinacrine, also known as mepacrine, has originally been used as an antimalarial drug for close to a century, but was recently rediscovered as an anticancer agent. The mechanisms of anticancer effects of quinacrine are not well understood. The anticancer potential of quinacrine was discovered in a screen for small molecule activators of p53, and was specifically shown to inhibit NFκB suppression of p53. However, quinacrine can cause cell death in cells that lack p53 or have p53 mutations, which is a common occurrence in many malignant tumors including high grade serous ovarian cancer. Recent reports suggest quinacrine may inhibit cancer cell growth through multiple mechanisms including regulating autophagy, FACT (facilitates chromatin transcription) chromatin trapping, and the DNA repair process. Additional reports also suggest quinacrine is effective against chemoresistant gynecologic cancer. In this review, we discuss anticancer effects of quinacrine and potential mechanisms of action with a specific focus on gynecologic and breast cancer where treatment-refractory tumors are associated with increased mortality rates. Repurposing quinacrine as an anticancer agent appears to be a promising strategy based on its ability to target multiple pathways, its selectivity against cancer cells, and the synergistic cytotoxicity when combined with other anticancer agents with limited side effects and good tolerability profile.
(Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: